<DOC>
	<DOC>NCT00239681</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.</brief_summary>
	<brief_title>JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events</brief_title>
	<detailed_description>AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Men 50 years or older, women 60 years or older Low to normal levels of low density lipoprotein (LDL) cholesterol (&lt; 130mg/dL) Elevated levels of CReactive Protein (CRP) &gt; 2.0 mg/L History of cardiovascular or cerebrovascular events Active liver disease Diabetes mellitus Uncontrolled hypertension or hypothyroidism History of certain malignancies Chronic inflammatory conditions History of alcohol or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Primary prevention</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Statin therapy</keyword>
	<keyword>C-reactive protein</keyword>
</DOC>